Prophylactic immunosuppression with anti-interleukin-2 receptor monoclonal antibody LO-Tact-1 versus OKT3 in liver allografting. A two-year follow-up study

Transplantation

Volumn 61, Issue 9, 1996, Pages 1406-1409

  Reding, Raymond ^a,b   Feyaerts, Axel ^a   Vraux, Hubert ^a   Latinne, Dominique ^a   De La Parra, Bernardo ^a   Cornet, Anne ^a   Cormont, Françoise ^a   Jamart, Jacques ^c   Sokal, Etienne ^a   De Ville De Goyet, Jean ^a   Lerut, Jan ^a   Bazin, Hervé ^a   Otte, Jean Bernard ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^c UNIVERSITY HOSPITAL OF MONT GODINNE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; INTERLEUKIN 2 RECEPTOR ANTIBODY; OKT 3; TACROLIMUS;

ALLOTRANSPLANTATION; ARTICLE; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SURVIVAL TIME;

ANTIBODIES, MONOCLONAL; COMMUNICABLE DISEASES; FOLLOW-UP STUDIES; GRAFT REJECTION; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSION; LIVER TRANSPLANTATION; MUROMONAB-CD3; PROSPECTIVE STUDIES; RECEPTORS, INTERLEUKIN-2; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 0029878231     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199605150-00022     Document Type: Article

References (11)

1. Soulillou JP, Cantarovich D, Le Mauff B, et al. Randomized controlled trial of a monoclonal antibody against the interleukin-2 receptor (33B3.1) as compared with rabbit antithymocyte globulin for prophylaxis against rejection of renal allografts. N Engl J Med 1990; 322: 1175.
2. Neuhaus P, Bechstein WO, Blumhardt G, et al. Comparison of quadruple immunosuppression after liver transplantation with ATG or IL-2 receptor antibody. Transplantation 1993; 55: 1320.
3. Reding R, Vraux H, de Ville de Goyet J, et al. Monoclonal antibodies in prophylactic immunosuppression after liver transplantation. A randomized controlled trial comparing OKT3 and anti-IL2 receptor LO-Tact-1. Transplantation 1993; 55: 534.
4. Cosimi AB, Jenkins RL, Rorher RJ, Delmonico FL, Hoffman M, Monaco AP. A randomized clinical trial of prophylactic OKT3 monoclonal antibody in liver allograft recipients. Arch Surg 1990; 125: 781.
5. McDiarmid S, Busuttil RW, Levy P, Millis JM, Terasaki PI, Ament ME. The long-term outcome of OKT3 compared with cyclosporine prophylaxis after liver transplantation. Transplantation 1991; 52: 91.
6. Friend PJ, Waldmann H, Cobbold S, et al. The anti-IL-2 receptor monoclonal antibody YTH-906 in liver transplantation. Transplant Proc 1991; 23: 1390.
7. Schlitt HJ, Nashan B, Krick P, et al. Intragraft immune events after human liver transplantation. Correlation with clinical signs of acute rejection and influence of immunosuppression. Transplantation 1992; 54: 273.
8. Dousset B, Hubscher SG, Padbury RTA, et al. Acute liver allograft rejection. Is treatment always necessary? Transplantation 1993; 55: 529.
9. Ravoet AM, Latinne D, Couvreur B, et al. CD25 mAb: epitopes recognized, effect on lymphocyte activation, mediation of ADCC. In: Knapp W, Dorken B, Gilks WR, et al., eds. Leucocyte typing IV. White cell differentiation antigens. Oxford: Oxford University Press, 1989: 408.
10. Tellides G, Dallman MJ, Morris PJ. Mechanism of action of interleukin-2 receptor (IL-2R) monoclonal antibody (MAb) therapy: target cell depletion or inhibition of function? Transplant Proc 1989; 21: 997.
11. Kupiec-Weglinski JW, Padberg W, Uhteg LC, et al. Selective immunosuppression with anti-interleukin 2 receptor-targeted therapy: helper and suppressor cell activity in rat recipients of cardiac allografts. Eur J Immunol 1987; 17: 313.